Samsung Bioepis Confirms Pharmacokinetic Equivalence in Phase 1 Trial of Keytruda Biosimilar
AI 요약 정보
- Samsung Bioepis reports SB27 PK equivalence to Keytruda
- Phase 1 trial enrolled 163 patients with NSCLC across 4 countries
- SB27's South Korean approval application covers 16 indications